课题基金 / 基金详情

Interactions of the SV40 Small T Antigen and PP2A in Human Cell Transformation

Interactions of the SV40 Small T Antigen and PP2A in Human Cell Transformation
SV40 小 T 抗原和 PP2A 在人类细胞转化中的相互作用
批准号:
6989676
负责人:
WILLIAM C HAHN
金额:
$12.82万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-04-27 至 2009-02-28

项目摘要

项目成果

WILLIAM C HAHN的其他基金

相似基金

相关文献

中文摘要
翻译
我们现在理解肿瘤转化是多个获得性基因改变的结果。这些聚合体的变化赋予了构成癌症临床特征的各种表型。尽管只有罕见的人类癌症源自病毒病因学,但对转化啮齿动物和人类细胞的DNA肿瘤病毒的研究已经让人们更好地理解了导致恶性状态的分子事件。特别是,对猿猴病毒40早期区(SV40 ER)所指定的病毒癌蛋白的研究揭示了关键的宿主细胞途径,其扰动在 哺乳动物细胞的实验性转化。我们最近的工作重新研究了两个SV40 ER癌蛋白,大T抗原(T)和小T抗原(T)在人类细胞转化中的作用。这两种癌蛋白的共同表达,加上端粒酶催化亚单位hTERT和H-RAS癌蛋白的致癌版本,足以转化人类细胞。T通过与视网膜母细胞瘤蛋白(PRB)和P53结合,使两条关键的肿瘤抑制通路失活。T转化人类细胞的能力需要与异三聚体蛋白磷酸酶2A(PP2A)的特定亚单位相互作用,PP2A是一个丰富的丝氨酸-苏氨酸磷酸酶家族。在这一应用中,我们建议使用分子生物学、遗传学和生化方法来研究导致人类 研究t与PP2A相互作用的后果将确定癌症发展的关键新途径以及癌症治疗的新靶点。
英文摘要
We now understand neoplastic transformation to be the consequence of multiple acquired genetic alterations. These changes in aggregate confer the various phenotypes that constitute the clinical features of cancer. Although only rare human cancers derive from a viral etiology, the study of DNA tumor viruses that transform rodent and human cells has led to a greater understanding of the molecular events that program the malignant state. In particular, investigation of the viral oncoproteins specified by the Simian Virus 40 Early Region (SV40 ER) has revealed critical host cell pathways, whose perturbation play an essential role in the experimental transformation of mammalian cells. Our recent work has re-investigated the roles of two SV40 ER oncoproteins, the large T antigen (T) and the small t antigen (t), in human cell transformation. Co-expression of these two oncoproteins, together with the telomerase catalytic subunit, hTERT, and an oncogenic version of the H-RAS oncoprotein, suffices to transform human cells. T inactivates two key tumor suppressor pathways by binding to the retinoblastoma protein (pRB) and p53. The ability of t to transform human cells requires interactions with specific subunits of the heterotrimeric protein phosphatase 2A (PP2A), an abundant family of serine-threonine phosphatases. In this application, we propose to use molecular biological, genetic, and biochemical approaches to investigate the molecular interactions that lead to human cell transformation by t. Investigating the consequences of the interaction of t with PP2A will identify new pathways critical for cancer development as well as novel targets for cancer therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
  • 批准号:
    10344246
  • 项目类别:
  • 资助金额:
    $68.27万
  • 财政年份:
    2022
  • 负责人:
    WILLIAM C HAHN
  • 依托单位:
Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models
  • 批准号:
    10186722
  • 项目类别:
  • 资助金额:
    $96.32万
  • 财政年份:
    2020
  • 负责人:
    WILLIAM C HAHN
  • 依托单位:
Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models
  • 批准号:
    10458506
  • 项目类别:
  • 资助金额:
    $96.37万
  • 财政年份:
    2020
  • 负责人:
    WILLIAM C HAHN
  • 依托单位:
PROJECT 4: Interrogating PP2A Signaling in Human Cancers
  • 批准号:
    10227785
  • 项目类别:
  • 资助金额:
    $32.64万
  • 财政年份:
    2017
  • 负责人:
    WILLIAM C HAHN
  • 依托单位:
海外基金